Evidence-Based Complementary and Alternative Medicine-20 Mar 2019 大黃素
時(shí)間：2020-09-03 瀏覽次數： 分享到：
Pharmacokinetic and Bioavailability Studies of Embelin after Intravenous and Oral Administration to Rats
期刊名：Evidence-Based Complementary and Alternative Medicine
文獻編號：DOI 10.1155/2019/9682495
文獻地址：https://www.hindawi.com/journals/ecam/2019/9682495/
發(fā)表日期：20 Mar 2019
Abstract
Embelin exhibits the broad bioactivities such as antitumor, antifertility, antidiabetic, anti-inflammatory, antioxidant, anticonvulsant, anxiolytic, antimicrobial, and hepatoprotective activity. In order to further understand the pharmacokinetic characteristics and oral bioavailability of embelin in vivo, the concentration of embelin in rat plasma was determined by a sensitive high-performance liquid chromatography with diode array detector (HPLC-DAD). The preparation of samples was accomplished by a simple precipitating protein with methanol. Emodin was selected as the internal standard (IS). Embelin and IS were completely separated on an analytical column (Extend-C18, 4.6 × 250 mm, 5 μm) using 0.1% phosphoric acid in methanol and 0.1% phosphoric acid in aqueous solution (90:10, v/v) as the mobile phase. The lower limit of quantification was 0.15 μg/mL. Oral bioavailability of embelin was 30.2 ± 11.9%. This study could provide the information about pharmacokinetics and oral bioavailability of embelin, which was useful to assess the clinic efficacy and safety and promote further development of embelin.
Emodin was purchased from Chengdu Desite Biological Technology Co., Ltd. (Chengdu, China)
